Related Experiment Videos
Systemic management of prostate cancer
L Balducci1, M Parker, H Hescock
1Hematology/Oncology Section, Bay Pines Veterans Hospital, FL 33504.
The American Journal of the Medical Sciences
|March 1, 1990
Summary
This review explores prostate cancer treatments, finding combined androgen blockade (CAB) and estramustine phosphate effective. Early or delayed treatment initiation remains under investigation for optimal outcomes.
Area of Science:
- Oncology
- Urology
Background:
- Metastatic adenocarcinoma of the prostate requires effective therapeutic strategies.
- Current treatments include orchiectomy, hormonal therapies, and antiandrogens.
Purpose of the Study:
- To review and compare various therapeutic options for metastatic prostate cancer.
- To evaluate the efficacy and complications of different treatment modalities.
Main Methods:
- Literature review of established and emerging treatments for advanced prostate cancer.
- Analysis of clinical trial data and treatment guidelines.
Main Results:
- Orchiectomy, estrogen therapy, LHRH analogs, and antiandrogens show similar efficacy as first-line treatments.
- Combined androgen blockade (CAB) offers superior efficacy over single-modality treatment in compliant patients.
- Ketoconazole is reserved for emergencies due to toxicity; estramustine phosphate is a viable alternative to CAB, especially for sexually active patients.
Conclusions:
- Treatment decisions for metastatic prostate cancer depend on patient compliance and specific clinical situations.
- Further research is needed to optimize the timing and combination of therapies, including CAB and estramustine, and to explore new cytotoxic agents.